MDI Health, an AI-powered platform that optimizes personalized medication treatment at scale, announced that the former Chief Medical Officer of Salesforce, Dr. Geeta Nayyar will join MDI Health’s advisory board. As a globally recognized healthcare technology leader, Dr. Nayyar is consulting with the industry’s most influential organizations and serving on the board of the American Telemedicine Association.
MDI’s AI technology solution personalizes and automates complex medication management to improve patient safety and reduce the total cost of care. Payors and Value-Based Providers, use MDI’s technology to prevent drug-related problems, maximize deprescribing efforts, reduce Rx costs, and see thousands of dollars PMPY in savings and over 20% reduction in medications per patient. Dr. Nayyar will be instrumental in guiding MDI’s clinical excellence and product strategy, as she brings extensive knowledge in leading technology companies such as Salesforce and AT&T as CMOs and leveraging innovations to achieve previously unimaginable health outcomes.
“MDI Health is using innovative technology to solve one of the most pressing healthcare issues, problems that stem from medication treatment. I am thrilled to join an organization driven by such an important mission and incredibly eager to support their commitment to advancing technology that not only drives incredible financial outcomes but most importantly, always keeps the patient front and center,” said Dr. Nayyar.
Dr. Nayyar is passionate about the significant transformation occurring within healthcare technology, especially with AI innovations that enable healthcare organizations to improve the quality of care through automation, personalization, and scale. Dr. Nayyar was deeply impressed by MDI’s role in this transformation and their impact on health and financial outcomes – leading to her joining the company.
Avishai Ben-Tovim, CEO and Co-founder of MDI Health commented: “We are thrilled to have a healthcare technology leader such as Dr. Nayyar join our team. Dr. Nayyar’s expertise and visionary leadership will be instrumental in steering our company towards groundbreaking achievements. Having esteemed clinical leaders such as Dr. Nayyar joining us in our mission speaks volumes to the work we are doing and the trajectory we are pursuing. I am confident that Dr. Nayyar’s guidance will be invaluable as we revolutionize how medication treatment is optimized with technology.”
Read Similar News:
Vizient’s 2025 Trends Report Offers a Strategy and Investment Roadmap for Healthcare Leaders
First Fertility Appoints Alison Bartolucci as New Chief Scientific Officer
